What is one of the main goals of biotherapy in oncology?

What is one of the main goals of biotherapy in oncology?

• A. To directly kill cancer cells
• B. To enhance the body's immune response to cancer
• C. To minimize the side effects of chemotherapy
• D. To provide genetic modifications for tumor cells

Answer: (B)

One of the main goals of biotherapy in oncology is to enhance the body's immune response to cancer. Biotherapy, also known as biological therapy or immunotherapy, leverages the body's own immune system to identify and combat cancer cells. This approach can include the use of agents such as monoclonal antibodies, vaccines, and cytokines, which stimulate the immune system to recognize and destroy cancerous cells more effectively. Enhancing the immune response is critical because a robust immune system can often identify cancer cells as foreign entities, leading to a more targeted and potentially effective attack. This strategy contrasts with traditional chemotherapy, which mainly targets rapidly dividing cells, regardless of whether they are cancerous or healthy. Therefore, biotherapy represents a shift towards more targeted therapies that utilize the body's natural defenses against tumors. In this context, while other options may relate to cancer treatment, they do not encapsulate the primary focus of biotherapy. Directly killing cancer cells is more characteristic of chemotherapy, minimizing chemotherapy side effects is irrelevant to biotherapy's primary function, and providing genetic modifications for tumor cells is not the goal of biotherapy, but rather a focus of other experimental treatments or gene therapy approaches.

One of the main goals of biotherapy in oncology is to enhance the body's immune response to cancer. Biotherapy, also known as biological therapy or immunotherapy, leverages the body's own immune system to identify and combat cancer cells. This approach can include the use of agents such as monoclonal antibodies, vaccines, and cytokines, which stimulate the immune system to recognize and destroy cancerous cells more effectively.

Enhancing the immune response is critical because a robust immune system can often identify cancer cells as foreign entities, leading to a more targeted and potentially effective attack. This strategy contrasts with traditional chemotherapy, which mainly targets rapidly dividing cells, regardless of whether they are cancerous or healthy. Therefore, biotherapy represents a shift towards more targeted therapies that utilize the body's natural defenses against tumors.

In this context, while other options may relate to cancer treatment, they do not encapsulate the primary focus of biotherapy. Directly killing cancer cells is more characteristic of chemotherapy, minimizing chemotherapy side effects is irrelevant to biotherapy's primary function, and providing genetic modifications for tumor cells is not the goal of biotherapy, but rather a focus of other experimental treatments or gene therapy approaches.